Cochrane · systematic review · CD006922
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Cates, CJ, Schmidt, S, Ferrer, M, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
8
No studies
2
Included studies
NR
No studies 2 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 10%Moderate 7 · 70%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySerious adverse events (SAEs) in adults and children
Population: adults and children with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adults and adolescents | no estimate extracted | NR | No studies |
All‐cause mortality | OR 0.8 [0.36, 1.78] | 41 studies · 27951 participants | Moderate Downgraded: imprecision |
All‐cause non‐fatal SAEc | OR 1.14 [0.97, 1.33] | 41 studies · 27951 participants | Moderate Downgraded: imprecision |
Asthma‐related mortality | no estimate extracted | 41 studies · 27951 participants | Moderate Downgraded: imprecision |
Asthma‐related non‐fatal SAEc | OR 1.15 [0.83, 1.59] | 41 studies · 27951 participants | Low Downgraded: imprecision |
Children | no estimate extracted | NR | No studies |
All‐cause mortality | no estimate extracted | 8 studies · 8453 participants | Moderate Downgraded: imprecision |
All‐cause non‐fatal SAEc | OR 1.04 [0.73, 1.48] | 8 studies · 8453 participants | Moderate Downgraded: imprecision |
Asthma‐related mortality | no estimate extracted | 8 studies · 8453 participants | Moderate Downgraded: imprecision |
Asthma‐related non‐fatal SAEc | OR 1.25 [0.72, 2.16] | 8 studies · 8453 participants | Moderate Downgraded: imprecision |
Serious adverse events
Population: Adults and children with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adults and adolescents | no estimate extracted | NR | No studies |
All cause mortality | OR 0.9 [0.31, 2.6] | 35 studies · 13447 participants | Moderate Downgraded: imprecision |
All cause non‐fatal SAE | OR 1.15 [0.91, 1.44] | 35 studies · 13447 participants | Moderate Downgraded: imprecision |
Asthma‐related SAE | OR 1.12 [0.65, 1.94] | 35 studies · 13447 participants | Moderate Downgraded: imprecision |
Children | no estimate extracted | NR | No studies |
All cause mortality | no estimate extracted | NR | No studies |
All cause non‐fatal SAE | OR 1.2 [0.37, 3.91] | 5 studies · 1862 participants | Moderate Downgraded: imprecision |
Asthma‐related SAE | OR 0.99 [0.06, 15.85] | 5 studies · 1862 participants | Moderate Downgraded: imprecision |
Serious adverse events
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ Adults and adolescents | OR 1.05 [0.32, 3.47] | 30 studies · 10873 participants | Moderate Downgraded: imprecision |
All‐cause non‐fatal SAE ‐ Adults | OR 1.17 [0.9, 1.52] | 30 studies · 10873 participants | Moderate Downgraded: imprecision |
All‐cause non‐fatal SAE ‐ Children | OR 0.75 [0.17, 3.31] | 3 studies · 1173 participants | Moderate Downgraded: imprecision |
Asthma‐related SAE ‐ Adults | OR 0.95 [0.52, 1.73] | 30 studies · 10873 participants | Moderate Downgraded: imprecision |
Asthma‐related SAE ‐ Children | OR 0.14 [0, 6.82] | 3 studies · 1173 participants | Moderate Downgraded: imprecision |